Nashville、TNにおける胃癌の臨床試験
Nashvilleとその周辺地域（約30マイル以内）の拠点で、胃癌に関する28件の研究が参加者を募集しています。研究を開いて、参加資格と連絡方法を確認してください。
公式研究テキスト（英語）
ここで研究参加者を募集していますか？ このページの上部に表示できます — 30日間 $99 →
A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
被験者募集中第2相
- SCRI Oncology Partners, Nashville
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
被験者募集中第2相
- SCRI Oncology Partners, Nashville
A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
被験者募集中第1相
- Sarah Cannon Research Institute (SCRI), Nashville
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)
被験者募集中第2/3相
- SCRI Oncology Partners, Nashville
- Tennessee Oncology, Nashville
Phase 3 Study of Cadonilimab Combined With Chemotherapy vs Chemotherapy in Combination With or Without Nivolumab for the 1L Treatment of Participants With HER2-negative, Previously Untreated, Unresectable or Metastatic Gastric/GEJ Adenocarcinoma
被験者募集中第3相
- Sarah Cannon Research Institute (SCRI) - Oncology Partners, Nashville
IKS014 in Advanced Solid Tumors That Express HER2
被験者募集中第1相
- Tennessee Oncology, Nashville
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
被験者募集中第1/2相
- Vanderbilt University Medical Center, Nashville
Clinical Trial of YH32367 in Patients With HER2 Positive Locally Advanced or Metastatic Solid Tumor
被験者募集中第1/2相
- Vanderbilt Ingram Cancer Center, Nashville
Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
被験者募集中第2相
- Research Site, Nashville
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
被験者募集中第1/2相
- Sarah Cannon Research Institue, Nashville
Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
被験者募集中第1/2相
- Sarah Cannon Research Institute, Nashville
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
被験者募集中第1相
- Sarah Cannon Research Institute, Nashville
Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
被験者募集中第3相
- Research Site, Nashville
A Phase 1/1b Study of IAM1363 in HER2 Cancers
被験者募集中第1相
- SCRI Oncology Partners, Nashville
- Vanderbilt Ingram Cancer Center, Nashville
A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors
被験者募集中第1相
- Sarah Cannon Research Institute, Nashville
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
被験者募集中第1/2相
- Sarah Cannon Research Institute Oncology Partners (SCRI-Nashville), Nashville
A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors
被験者募集中第1相
- Sarah Cannon Research Institute - Pharmacy, Nashville
- SCRI Oncology Partners, Nashville
A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors
被験者募集中第1相
- SCRI Oncology Partners, Nashville
A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
被験者募集中第2相
- SCRI Oncology Partners, Nashville
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
被験者募集中第1相
- US Oncology Research LLC, Nashville
Pilot Study of [68Ga]Ga-ABY-025 Imaging in Patients Undergoing Treatment With HER2-targeted Therapy
被験者募集中早期第1相
- Vanderbilt University Medical Center, Nashville
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
被験者募集中第1/2相
- Sarah Cannon Research Institute, Nashville
Gastrointestinal Biomarkers in Tissue and Biological Fluid Samples From Colorectal Cancer Patients
被験者募集中観察研究
- Veterans Affairs Medical Center - Nashville, Nashville
- Vanderbilt-Ingram Cancer Center, Nashville
A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer
被験者募集中第3相
- Vanderbilt University Medical Center, Nashville
- HCA Midwest Health, Nashville
A Phase 1/2 Study to Evaluate CHM-2101, an Autologous Cadherin 17 Chimeric Antigen Receptor (CAR) T Cell Therapy
被験者募集中第1/2相
- Sarah Cannon Research Institute, Nashville
cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
被験者募集中観察研究健康なボランティア歓迎
- Vanderbilt-Ingram Cancer Center, Nashville
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
被験者募集中観察研究
- Massive Bio SYNERGY-AI site, Nashville
A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors
被験者募集中第1/2相
- Tennessee Oncology, Nashville
他の都市における胃癌の試験
- Houston, TX42件の研究
- Boston, MA32件の研究
- New York City, NY31件の研究
- Baldwin Park, CA22件の研究
- Los Angeles, CA22件の研究
- Arlington, VA20件の研究
- Dallas, TX19件の研究
- San Antonio, TX19件の研究
- St. Louis, MO18件の研究
- Grand Rapids, MI18件の研究
- Washington, DC16件の研究
- Chicago, IL16件の研究
Nashvilleにおける他の研究
- 非小細胞肺癌97件の研究
- 乳がん81件の研究
- 転移性癌70件の研究
- 大腸癌69件の研究
- がん（全種類）65件の研究
- 卵巣がん49件の研究
- 前立腺がん43件の研究
- 肺がん40件の研究
- 頭頸部扁平上皮癌39件の研究
- 膵臓がん39件の研究
- 子宮内膜がん38件の研究
- 悪性黒色腫33件の研究
ClinicalTrials.govより、2026/10/06時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。